Search This Blog

Monday, December 29, 2025

Praxis rises on ulixacaltamide gaining Breakthrough Therapy status

 


Praxis Precision Medicines gains FDA Breakthrough Therapy status for ulixacaltamide in essential tremor.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.